europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

EuropaBio response to the EGE report ‘Ethics of Genome Editing’

31/03/2021
PRESS RELEASE

EuropaBio response to the EGE report ‘Ethics of Genome Editing’

Brussels, 31 March 2021 - EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet. We strongly support the Group’s call to apply genome editing on the basis of appropriate and proportionate control, with core values of diversity, respect and responsibility. Genome editing in key applications are promising next step in research towards beneficial uses in medicine, agriculture and the bioeconomy aimed at addressing some of society’s grand challenges.

For a sustainable and competitive Europe
Within industrial processes, genome editing is an important tool for improving microorganisms used as products themselves or used to produce fermentation products used in sectors such as food and feed, agriculture, fuels and chemicals, and thereby enable the circular bioeconomy. These products are a major alternative to ingredients derived through petro-chemical sources or processes and hold the key to Europe achieving a bio-circular economy.

For a healthy Europe
Within medicine, genome editing offers the prospect of saving lives and addressing some of the most devastating genetic diseases. Clinical research with genome editing of human non-heritable (somatic) cells is currently seeking to develop treatments for HIV, leukaemia, haemophilia, Leber’s congenital amaurosis 10, mucopolysaccharidosis, sickle cell disease and cystic fibrosis, amongst others.

Pre-clinical and human clinical testing by EuropaBio member companies that uses genome editing for the treatment of genetically based diseases, is undertaken on non-heritable (somatic) cells, setting the standard for responsible innovation. EuropaBio encourages the EU to engage with the global community, involving government, academia, industry and society, to discuss the research, clinical, legal, societal, and ethical issues associated with genome editing of human germline cells and embryos, to establish a responsible and responsive global governance framework. The recommended creation of a European Platform for information sharing and inclusive debate on germline genome editing will greatly facilitate that process.

An established governance framework will allow clinical research in genome editing of human germline cells and embryos, carried out only with the intention to prevent and/or provide therapies to serious and unmet patient needs. EuropaBio does not support the conduct of research in germline genome editing aimed at achieving human enhancement.

Download the full PRESS RELEASE below.

EuropaBio response to the EGE report ‘Ethics of Genome Editing’


Download
2021_03_G_PR_EuropaBio-response-to-the-EGE-report-‘Ethics-of-Genome-EditingDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies